---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-227712"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2023-09-01T23:59:59+00:00"
generated_at: "2026-06-11T00:46:28.105599+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology enters $7M ATM equity facility with ThinkEquity LLC

## Summary
- MAIA may sell up to $7,000,000 of common stock at market prices through ThinkEquity as sales agent.
- Fixed commission rate of 3.0% of gross proceeds; agent also receives expense reimbursement up to $50,000 upfront.
- Sales are subject to a placement notice process and can be suspended by either party on 10 days' notice.
- Agreement filed as Exhibit 10.1; shares offered pursuant to effective S-3 shelf registration statement.
- No obligation to sell; proceeds expected for general corporate purposes per prospectus supplement.

## SEC filing metadata
- accession: 0001193125-23-227712
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2023-09-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000119312523227712/0001193125-23-227712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000119312523227712/d482665d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-227712
- JSON: https://secwatch.observer/filing/0001193125-23-227712.json
- Plain text: https://secwatch.observer/filing/0001193125-23-227712.txt

## Key facts
- Material Agreements
  MAIA Biotechnology, Inc. entered into Sales Agreement with ThinkEquity LLC valued at up to $7,000,000 (effective 2023-09-01).
  - Action: entry
  - Agreement: atm program
  - Counterparty: ThinkEquity LLC
  - Value: up to $7,000,000
  - Effective: 2023-09-01
  source text: On September 1, 2023, MAIA Biotechnology, Inc. (the “Company”), entered into an “at-the-market” Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $7,000,000, subject to the terms and conditions of the Sales Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000119312523227712/0001193125-23-227712-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.